医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Elekta: Enhanced collaboration with Toshiba strengthens Elekta’s position in Japan

2014年09月01日 PM02:55
このエントリーをはてなブックマークに追加


 

TOKYO

Regulatory News:

In an agreement signed today in Tokyo, Elekta Japan will grant Toshiba Medical Systems Corporation (TMSC) wider distribution rights regarding linear accelerator (linac) sales. The agreement builds on a sales and marketing agreement from 2010 (http://www.elekta.com/press/44337b95-6e69-4e41-926d-aaa6d6dbf002/elekta-signs-sales-and-marketing-agreement-with-toshiba-in-japan-.html).

Shuichi Higaki, President and Managing Director, Elekta Japan, says: “The existing partnership between Elekta and TMSC from 2010 has helped raise Elekta’s profile in the Japanese market. This new agreement creates significant opportunities for Elekta to further increase our customer satisfaction and become the leading supplier of oncology systems and related software solutions in Japan.”

Since Siemens’s departure from the linac market in 2011, TMSC still has an installed base of about 200 aging Siemens linear accelerators. The extended partnership opens up additional sales channels for Elekta’s linacs and software products and gives Elekta the opportunity to convert existing Siemens LANTIS Oncology Information Systems that were sold through TMSC.

The agreement also includes the intention to develop the Elekta Support Center, a centralized customer support center with a single point of contact for all Elekta linac users in Japan. Elekta will continue to manage marketing and promotion of all Elekta products and solutions, as well as education and training and software service support.

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on September 1, 2014.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

This information was brought to you by Cision http://news.cision.com

CONTACT

For further information, please contact:
Gert van Santen, Group
Vice President Corporate Communications, Elekta AB
Tel: +31 653 561
242, e-mail: gert.vansanten@elekta.com
Time
zone: CET: Central European Time
or
Johan Andersson, Director,
Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time
zone: CET: Central European Time

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment